
We Claim:

1. A compound of formula (I):



(I)

or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof; wherein

------ represents single bond or double bond;

$-X_1-X_2-$ represents $-CR_{X1}-CR_{X2}-$, $-N-CR_{X2}-$ or $-CR_{X1}-N-$;

R_{X1} and R_{X2} independently represents hydrogen, $-OR_a$, alkyl, alkynyl-OH, $-N(alkyl)_2$, cycloalkyl, heterocycloalkyl or heteroaryl; wherein the cycloalkyl, heterocycloalkyl and heteroaryl are optionally substituted with 1 to 3 substituent(s) selected from alkyl, acyl, halogen, -CN, oxo, $-NH_2$, –OH, -NHCO-alkyl, $-SO_2NH_2$ and –CONH-alkyl;

R_a represents hydrogen, alkyl, haloalkyl, alkoxy, (heterocycloalkyl)alkyl-, heterocycloalkyl, heteroaryl, (heteroaryl)alkyl-; wherein the alkyl, at each occurrence, is optionally substituted with 1 to 3 substituent(s) independently selected from -OH, –COOH, -COO-alkyl, alkoxy, $-NH(alkyl)_2$, -CONH-O-alkyl and heterocycloalkyl; and wherein the heterocycloalkyl and heteroaryl are optionally substituted with 1 to 3 substituent(s) independently selected from alkyl, oxo and acyl;

Q_1 represents 5- to 7-membered heterocycloalkyl ring;

Q_2 represents fused 5- to 6-membered heteroaryl ring or fused benzo ring;

R_1 represents hydrogen, alkyl or haloalkyl;

R_2 represents hydrogen, alkyl or $–NH_2$;

R_3, at each occurrence, independently, represents hydrogen, halogen, –CN, alkyl, alkoxy, haloalkyl, -CHO, acyl, -CONH-alkyl, -COO-alkyl, -COOH, -OH, $-SO_2NH_2$, $-SO_2NH$-alkyl, $-SO_2N(alkyl)_2$, $-SO_2NH$-aryl, -SO-alkyl, $-SO_2$-alkyl, $-SO_2NHCO$-alkyl, $-SO_2NHCO$-haloalkyl, -S(O)(NH)-alkyl, $-NHSO_2$-alkyl, -NHCO-alkyl, -N(alkyl)CO-alkyl, heteroaryl,

heterocycloalkyl, carbocyclyl or cycloalkyl; wherein the alkyl, at each occurrence, is optionally substituted with 1 to 3 occurrence(s) of R_{3A}; the heteroaryl is optionally substituted with 1 to 3 occurrence(s) of R_{3B}; and heterocycloalkyl is optionally substituted with 1 to 3 occurrence(s) of R_{3C};

$R_{3A,}$ at each occurrence, independently, is alkoxy, –OH, -CONHOH or -NHCO-alkyl;

$R_{3B,}$ at each occurrence, independently, is alkyl, alkoxy, –OH, -COOH, oxo, -COO-alkyl, -CONH-alkyl or -CONH-OH;

$R_{3C,}$ at each occurrence, independently, at each occurrence, independently, is alkyl, -CN, –OH, $-NH_2$, $-N(alkyl)_2$, acyl, oxo, -CONH-alkyl, -NHCO-alkyl or –CONH-alkyl-OH;

$R_{4,}$ at each occurrence, independently, represents hydrogen, alkyl, haloalkyl, acyl, -CONH-alkyl, oxo, $-SO_2$-alkyl, aralkyl, heteroaryl, heterocycloalkyl or cycloalkyl; wherein the alkyl, aryl, heteroaryl and heterocycloalkyl are optionally substituted with 1 to 3 occurrence(s) of R_{4A};

$R_{4A,}$ at each occurrence, independently, is alkoxy, $-COOCH_2CH_3$, -COOH or -CONH-alkyl;

m is 1, 2, 3 or 4; and

n is 1, 2, 3 or 4.

2. The compound of claim 1, wherein $-X_1-X_2-$ represents $-CR_{X1}-CR_{X2}-$.

3. The compound of claim 1, wherein $-X_1-X_2-$ represents $-CR_{X1}-N-$.

4. The compound of claim 1, wherein R_1 represents alkyl or haloalkyl; and R_2 represents alkyl or amino.

5. The compound of claim 1, wherein R_1 represents hydrogen, $-CH_3$, $-CH_2CH_3$ or $-CHF_2$.

6. The compound of claim 1, wherein R_2 represents hydrogen, $-CH_3$, $-CH_2CH_3$ or $-NH_2$.

7. The compound of claim any one of claims 1 to 6, wherein R_{X1} represents hydrogen, –OR_a, $-CH_3$, $-C{\equiv}CCH_2OH$, $-N(CH_3)_2$, azetidinyl, furanyl, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, dihydropyranyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 3-oxa-6-azabicyclo[3.1.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 2-oxa-6-azaspiro[3.4]octanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, cyclohexanyl, imidazolyl or isooxazolyl, wherein each cyclic group is optionally substituted

with 1 to 3 substituent(s) independently selected from –CH_3, -$COCH_3$, -F, -CN, oxo, -NH_2, –OH, -$NHCOCH_3$, -SO_2NH_2 and –$CONHCH_3$.


8. The compound of claim 7, wherein R_a represents -CH_3, -$CH(CH_3)_2$, -CH_2-$COOC(CH_3)_3$, -CH_2-piperidinyl(CH_3), -CH_2-CH_2-morpholine, -CH_2-CH_2-OCH_3, -CH_2-CH_2-$N(CH_3)_2$, azetidinyl, -CH_2-oxazole, -CH_2-CH_2-OH, -CH_2-CH_2-piperizinyl($COCH_3$), -CH_2-COOH, -CH_2-$CONH(OCH_3)$, -CHF_2 or -CH_2-CHF_2.

9. The compound of any one of claims 1 to 8, wherein R_{X2} represents hydrogen or alkyl.

10. The compound of any one of claims 1 to 9, wherein Q_1 represents 5- to 6-membered heterocycloalkyl ring.

11. The compound of any one of claims 1 to 9, wherein Q_1 represents 6-membered heterocycloalkyl ring.

12. The compound of any one of claims 1 to 11, wherein Q_1 represents




; wherein ------ represents point of attachment to the ring containing X_1 and X_2; and ∿∿∿ represents the points of fusion with Q_2.


13. The compound of any one of claims 1 to 12, wherein Q_2 represents fused 5- to 6-membered heteroaryl ring.


14. The compound of any one of claims 1 to 12, wherein Q_2 represents fused benzo ring.

15. The compound of any one of claims 1 to 14, wherein Q_2 represents



; wherein ∿∿∿ represents the points of fusion with Q_1.

16. The compound of any one of claims 1 to 15, wherein  represents



17. The compound of claim 1, wherein R_3, at each occurrence, independently, represents hydrogen, halogen, –CN, alkyl, alkoxy, haloalkyl, -CHO, acyl, -CONH-alkyl, -COO-alkyl, -COOH, oxo, -OH, $-SO_2NH_2$, $-SO_2NH$-alkyl, $-SO_2N(alkyl)_2$, $-SO_2NH$-aryl, -SO-alkyl, $-SO_2$-alkyl, $-SO_2NHCO$-alkyl, $-SO_2NHCO$-haloalkyl, -S(O)(NH)-alkyl, $-NHSO_2$-alkyl, -NHCO-alkyl, -N(alkyl)CO-alkyl, heteroaryl, heterocycloalkyl, carbocyclyl or cycloalkyl; wherein the alkyl , at each occurrence, are optionally substituted with 1 to 3 occurrence(s) of R_{3A}; the heteroaryl is optionally substituted with 1 to 3 occurrence(s) of R_{3B}; and heterocycloalkyl is optionally substituted with 1 to 3 occurrence(s) of R_{3C}.

18. The compound of claim 1, wherein R_4, at each occurrence, independently, represents hydrogen, alkyl, haloalkyl, acyl, -CONH-alkyl, oxo, $-SO_2$-alkyl, aralkyl, heteroaryl, heterocycloalkyl or cycloalkyl; wherein the alkyl, aryl, heteroaryl and heterocycloalkyl are optionally substituted with 1 to 3 occurrence(s) of R_{4A}.

19. The compound of claim 1, wherein


------ represents single bond or double bond;

$-X_1-X_2-$ represents $-CR_{X1}-CR_{X2}-$, $-N-CR_{X2}-$ or $-CR_{X1}-N-$;


R_{X1} represents hydrogen, $-OR_a$, $-CH_3$, $-C\equiv CCH_2OH$, $-N(CH_3)_2$, azetidinyl, furanyl, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, dihydropyranyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 3-oxa-6-azabicyclo[3.1.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 2-oxa-6-azaspiro[3.4]octanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, cyclohexanyl, imidazolyl or isooxazolyl; wherein each cyclic group is optionally substituted with 1 to 3 substituent(s) independently selected from $-CH_3$, $-COCH_3$, -F, -CN, oxo, $-NH_2$, –OH, $-NHCOCH_3$, $-SO_2NH_2$ and $-CONHCH_3$;

R_{X2} represents hydrogen or $-CH_3$;

R_a represents $-CH_3$, $-CH(CH_3)_2$, $-CH_2-COOC(CH_3)_3$, $-CH_2$-piperidinyl(CH_3), $-CH_2-CH_2$-morpholine, $-CH_2-CH_2-OCH_3$, $-CH_2-CH_2-N(CH_3)_2$, azetidinyl, $-CH_2$-oxazole, $-CH_2-CH_2-OH$, $-CH_2-CH_2$-piperizinyl$(COCH_3)$, $-CH_2-COOH$, $-CH_2-CONH(OCH_3)$, $-CHF_2$ or $-CH_2-CHF_2$;



represents




or ;

R_3, at each occurrence, independently, represents hydrogen, $-CH_3$, $-CH_2OH$, $-CH_2CONHOH$, -F, –CN, $-OCH_3$, $-CHF_2$, $-CF_3$, -CHO, acyl, $-CONHCH_3$, $-COOCH_3$, -COOH, oxo, -OH, $-SO_2NH_2$, $-SO_2NHCH_3$, $-SO_2N(CH_3)_2$, $-SO_2NH$(phenyl), $-SOCH_3$, $-SO_2CH_3$, $-SO_2CH(CH_3)_2$, $-SO_2NHCOCH_3$, $-SO_2NHCOCF_3$, $-S(O)(NH)CH_3$, $-NHSO_2CH_3$, $-NHSO_2CH_2CH_3$, $-NHSO_2CH(CH_3)_3$, $-NHCOCH_3$, $-N(CH_3)COCH_3$, pyrazolyl, pyridyl, tetrazolyl, thienyl, 2H-pyridyl, dihydropyridyl, dihydrooxazolyl, tetrahydrofuranyl, morpholinyl, piperazinyl, pyrrolidinyl, piperidinyl or azetidinyl;

wherein the pyrazolyl, pyridyl, tetrazolyl and thienyl are optionally substituted with 1 to 3 substituent(s) independently selected from methyl, ethyl, methoxy, –OH, -COOH, oxo, -COO-alkyl, -CONH-alkyl or -CONH-OH; and the 2H-pyridyl, dihydropyridyl, dihydrooxazolyl, tetrahydrofuranyl, morpholinyl, piperazinyl, pyrrolidinyl, piperidinyl and azetidinyl are optionally substituted with 1 to 3 substituent(s) independently selected from -CN, –OH, $-NH_2$, $-N(CH_3)_2$, $-COCH_3$, oxo, $-CONHCH_3$, $-NHCOCH_3$ and $–CONHCH_2CH_2OH$;

R_4, at each occurrence, independently, represents hydrogen, $-CH_3$, $-CH_2CH_3$, $-CH_2COOH$, $-CH_2(p\text{-}(OCH_3)\text{phenyl})$, $-CHF_2$, $-COCH_3$, $-CH_2COOCH_2CH_3$, $-CH_2CONHCH_3$, $-CONHCH_3$, oxo, $-SO_2CH_2CH_3$, morpholinyl, pyranyl or cyclopropyl.

20. The compound of claim 1, represented by compound of formula (IA):




(IA)


or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof; wherein X_3 represents N, O, S or C; and p is 0, 1 or 2.

21. The compound of claim 20, wherein X_3 represents N, S or C.

22. The compound of claim 20, wherein Q_2 represents




or



.

23. The compound of any one of claims 20 to 22, wherein the formula

represents



24. The compound of any one of claims 20 to 23, wherein


R_1 and R_2 independently represents hydrogen or –CH_3;

$-X_1-X_2-$ represents $-CR_{X1}-CR_{X2}-$, $-N-CR_{X2}-$ or $-CR_{X1}-N-$;

R_{X1} represents hydrogen, –OR_a, -CH_3, -$C{\equiv}CCH_2OH$, -$N(CH_3)_2$, azetidinyl, furanyl, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, dihydropyranyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 3-oxa-6-azabicyclo[3.1.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 2-oxa-6-azaspiro[3.4]octanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, cyclohexanyl, imidazolyl or isooxazolyl; wherein each cyclic group is optionally substituted with 1 to 3 substituent(s) independently selected from –CH_3, -$COCH_3$, -F, -CN, oxo, -NH_2, –OH, -$NHCOCH_3$, -SO_2NH_2 and –$CONHCH_3$;

R_{X2} represents hydrogen or alkyl;

R_a represents hydrogen, alkyl, haloalkyl, alkoxy, (heterocycloalkyl)alkyl-, heterocycloalkyl, heteroaryl or (heteroaryl)alkyl-; wherein the alkyl, at each occurrence, is optionally substituted by 1 to 3 substituent(s) independently selected from heterocycloalkyl, –COOH, alkoxy, -$NH(alkyl)_2$ and -CONH-O-alkyl; and wherein the heterocycloalkyl and heteroaryl are optionally substituted by 1 to 3 substituent(s) independently selected from alkyl and acyl;

the formula  represents ;


R_3, at each occurrence, independently, represents –CH_3, –CH_2OH, -$CH_2CONHOH$, -F, –CN, -OCH_3, -CHF_2, -CF_3, -CHO, acyl, -$CONHCH_3$, -$COOCH_3$, -

COOH, oxo, -OH, $-SO_2NH_2$, $-SO_2NHCH_3$, $-SO_2N(CH_3)_2$, $-SO_2NH$(phenyl), $-SOCH_3$, $-SO_2CH_3$, $-SO_2CH(CH_3)_2$, $-SO_2NHCOCH_3$, -SO2NHCOCF3, $-S(O)(NH)CH_3$, $-NHSO_2CH_3$, $-NHSO_2CH_2CH_3$, $-NHSO_2CH(CH_3)_3$, $-NHCOCH_3$, $-N(CH_3)COCH_3$, pyrazolyl, pyridyl, tetrazolyl, thienyl, 2H-pyridyl, dihydropyridyl, dihydrooxazolyl, tetrahydrofuranyl, morpholinyl, piperazinyl, pyrrolidinyl, piperidinyl or azetidinyl; wherein the pyrazolyl, pyridyl, tetrazolyl and thienyl are optionally substituted with 1 to 3 substituent(s) independently selected from alkyl, alkoxy, –OH, -COOH, oxo, -COO-alkyl, -CONH-alkyl and -CONH-OH; and the 2H-pyridyl, dihydropyridyl, dihydrooxazolyl, tetrahydrofuranyl, morpholinyl, piperazinyl, pyrrolidinyl, piperidinyl and azetidinyl are optionally substituted with 1 to 3 substituent(s) independently selected from $–CH_3$, -CN, –OH, $-NH_2$, $-N(CH_3)_2$, $-COCH_3$, oxo, $-CONHCH_3$, $-NHCOCH_3$ and $–CONHCH_2CH_2OH$;

R_4, at each occurrence, independently, represents hydrogen, $-CH_3$, $-CH_2CH_3$, $-CH_2COOH$, $-CH_2$(*p*-(OCH_3)phenyl), $-CHF_2$, $-COCH_3$, $-CH_2COOCH_2CH_3$, $-CH_2CONHCH_3$, $-CONHCH_3$, oxo, $-SO_2CH_2CH_3$, morpholinyl, pyranyl or cyclopropyl; and

n is 1, 2 or 3.

25. The compound of claim 1, represented by compound of formula (IB):



(IB)

or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof.

26. The compound of claim 25, wherein


X_2 represents CH or N;

R_{X1} represents hydrogen, $–OR_a$, $-CH_3$, $-C{\equiv}CCH_2OH$, $-N(CH_3)_2$, azetidinyl, furanyl, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, dihydropyranyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 3-oxa-6-azabicyclo[3.1.1]heptanyl,

2-oxa-6-azaspiro[3.3]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 2-oxa-6-azaspiro[3.4]octanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, cyclohexanyl, imidazolyl or isooxazolyl; wherein each cyclic group is optionally substituted with 1 to 3 substituent(s) independently selected from –CH_3, -$COCH_3$, -F, -CN, oxo, -NH_2, –OH, -$NHCOCH_3$, -SO_2NH_2 and –$CONHCH_3$;

R_a represents -CH_3, -$CH(CH_3)_2$, -CH_2-$COOC(CH_3)_3$, -CH_2-piperidinyl(CH_3), -CH_2-CH_2-morpholine, -CH_2-CH_2-OCH_3, -CH_2-CH_2-$N(CH_3)_2$, azetidinyl, -CH_2-oxazole, -CH_2-CH_2-OH, -CH_2-CH_2-piperizinyl($COCH_3$), -CH_2-COOH, -CH_2-$CONH(OCH_3)$, -CHF_2 or -CH_2-CHF_2;

Q_2 represents



;

R_3, at each occurrence, independently, represents hydrogen, –CH_3, –CH_2OH, -$CH_2CONHOH$, -F, –CN, -OCH_3, -CHF_2, -CF_3, -CHO, acyl, -$CONHCH_3$, -$COOCH_3$, -COOH, oxo, -OH, -SO_2NH_2, -SO_2NHCH_3, -$SO_2N(CH_3)_2$, -SO_2NH(phenyl), -$SOCH_3$, -SO_2CH_3, -$SO_2CH(CH_3)_2$, -$SO_2NHCOCH_3$, -$SO_2NHCOCF3$, -$S(O)(NH)CH_3$, -$NHSO_2CH_3$, -$NHSO_2CH_2CH_3$, -$NHSO_2CH(CH_3)_3$, -$NHCOCH_3$, -$N(CH_3)COCH_3$, pyrazolyl, pyridyl, tetrazolyl or thienyl; wherein the pyrazolyl, pyridyl, tetrazolyl and thienyl are optionally substituted with 1 to 3 substituent(s) independently selected from alkyl, alkoxy, –OH, -COOH, oxo, -COO-alkyl, -CONH-alkyl and -CONH-OH;


R_4, at each occurrence, independently, represents hydrogen, -CH_3, -CH_2CH_3, -CH_2COOH, -CH_2(*p*-(OCH_3)phenyl), -CHF_2, -$COCH_3$, -$CH_2COOCH_2CH_3$, -$CH_2CONHCH_3$, -$CONHCH_3$, oxo, -$SO_2CH_2CH_3$, morpholinyl, pyranyl or cyclopropyl; wherein morpholinyl, pyranyl and cyclopropyl are optionally substituted with 1 to 3 substituent(s) independently selected from -OCH_3, -$COOCH_2CH_3$, -COOH and –$CONHCH_3$;

X_3 represents N, O, S or C;

p is 0, 1 or 2; and

n is 1, 2 or 3.

27. The compound of claim 1, represented by compound of formula (IC):



(IC)

or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof.

28. The compound of claim 27, wherein

X_2 represents CH or N;

R_{X1} represents hydrogen, –OR_a, -CH_3, -C≡CCH_2OH, -$N(CH_3)_2$, azetidinyl, furanyl, pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl dihydropyranyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 3-oxa-6-azabicyclo[3.1.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 2-oxa-6-azaspiro[3.4]octanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, cyclohexanyl, imidazolyl or isooxazolyl; wherein each cyclic group is optionally substituted with 1 to 3 substituent(s) independently selected from –CH_3, -$COCH_3$, -F, -CN, oxo, -NH_2, –OH, -$NHCOCH_3$, -SO_2NH_2 and –$CONHCH_3$;

R_a represents -CH_3, -$CH(CH_3)_2$, -CH_2-$COOC(CH_3)_3$, -CH2-piperidinyl(CH_3), -CH_2-CH_2-morpholine, -CH_2-CH_2-OCH_3, -CH_2-CH_2-$N(CH_3)_2$, azetidinyl, -CH_2-oxazole, -CH_2-CH_2-OH, -CH_2-CH_2-piperizinyl($COCH_3$), -CH_2-COOH, -CH_2-$CONH(OCH_3)$, -CHF_2 or -CH_2-CHF_2;


R_3, at each occurrence, independently, represents –CH_3, –CH_2OH, -$CH_2CONHOH$, -F, –CN, -OCH_3, -CHF_2, -CF_3, -CHO, acyl, -$CONHCH_3$, -$COOCH_3$, -COOH, oxo, -OH, -SO_2NH_2, -SO_2NHCH_3, -$SO_2N(CH_3)_2$, -SO_2NH(phenyl), -$SOCH_3$, -SO_2CH_3, -$SO_2CH(CH_3)_2$, -$SO_2NHCOCH_3$, -$SO_2NHCOCF3$, -$S(O)(NH)CH_3$, -$NHSO_2CH_3$, -$NHSO_2CH_2CH_3$, -$NHSO_2CH(CH_3)_3$, -$NHCOCH_3$, -$N(CH_3)COCH_3$, pyrazolyl, pyridyl, tetrazolyl or thienyl; wherein the pyrazolyl, pyridyl, tetrazolyl or thienyl is optionally substituted with 1 to 3 substituent(s) independently selected from alkyl, alkoxy, –OH, -COOH, oxo, -COO-alkyl, -CONH-alkyl and -CONH-OH;

R_4, at each occurrence, independently, represents hydrogen, -CH_3, -CH_2CH_3, -CH_2COOH, -CH_2(*p*-(OCH_3)phenyl), -CHF_2, -$COCH_3$, -$CH_2COOCH_2CH_3$, -$CH_2CONHCH_3$, -$CONHCH_3$, oxo, -$SO_2CH_2CH_3$, morpholinyl, pyranyl or cyclopropyl; wherein morpholinyl, pyranyl and cyclopropyl are optionally substituted with 1 to 3 substituent(s) independently selected from -OCH_3, -$COOCH_2CH_3$, -COOH and –$CONHCH_3$;

m is 1, 2 or 3; and

n is 1, 2 or 3.

29. The compound of claim 1, represented by compound of formula (ID),



(ID)

or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof.

30. The compound of claim 29, wherein

X_2 represents CH or N;

R_{X1} represents hydrogen, –OR_a, -CH_3, -$CH(CH_3)_2$, -C≡CH_2OH, piperidinyl, morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 3-oxa-6-azabicyclo[3.1.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 2-oxa-6-azaspiro[3.4]octanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, cyclohexanyl, imidazolyl or isooxazolyl; wherein each cyclic group is optionally substituted with 1 to 3 substituent(s) independently selected from –CH_3, -$COCH_3$, -NH_2, –OH, -SO_2NH_2 and –$CONHCH_3$;

R_a represents hydrogen, -CH_3, -$CH(CH_3)_2$, -CH_2-$COOC(CH_3)_3$, -CH_2-piperidinyl(CH_3), -CH_2-CH_2-morpholine, -CH_2-CH_2-OCH_3, -CH_2-CH_2-$N(CH_3)_2$, azetidinyl, -CH_2-CH_2-OH, -CH_2-CH_2-piperizinyl($COCH_3$) or -CH_2-COOH;

R_3, at each occurrence, independently, represents alkyl, haloalkyl, acyl, oxo, -OH, heteroaryl, heterocycloalkyl or cycloalkyl, wherein the alkyl, at each occurrence,

is optionally substituted with 1 to 3 occurrence(s) of R_{3A}; the heteroaryl is optionally substituted with 1 to 3 occurrence(s) of R_{3B}; and heterocycloalkyl is optionally substituted with 1 to 3 occurrence(s) of R_{3C};

$R_{3A,}$ at each occurrence, independently, is alkoxy, –OH, -CONHOH or -NHCO-alkyl;

$R_{3B,}$ at each occurrence, independently, is alkyl, alkoxy, –OH, -COOH, oxo, -COO-alkyl, -CONH-alkyl or -CONH-OH;


$R_{3C,}$ at each occurrence, independently, is alkyl, -CN, –OH, $-NH_2$, $-N(alkyl)_2$, acyl, oxo, -CONH-alkyl, -NHCO-alkyl or –CONH-alkyl-OH;

$R_{4,}$ at each occurrence, independently, represents hydrogen, $-CH_3$, $-CH_2CH_3$, $-CH_2COOH$, $-CH_2(p\text{-}(OCH_3)phenyl)$, $-CHF_2$, $-COCH_3$, $-CH_2CONHCH_3$, $-CONHCH_3$;

m is 1, 2 or 3; and

n is 1, 2 or 3.

31. The compound of claim 1, represented by compound of formula (IE),



(IE)

or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof.

32. The compound of claim 31, wherein

X_2 represents CH or N;

R_{X1} represents hydrogen, $–OR_a$, $-CH_3$, $-CH(CH_3)_2$, $-C{\equiv}CCH_2OH$, piperidinyl, morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octanyl, 3-oxa-6-azabicyclo[3.1.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, 2-oxa-6-azaspiro[3.4]octanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, cyclohexanyl, imidazolyl or isooxazolyl; wherein each cyclic group is optionally substituted with 1 to 3 substituent(s) independently selected from $–CH_3$, -CN, $-NH_2$ and –OH;

R_a represents hydrogen, $-CH_3$, $-CH(CH_3)_2$, $-CH_2-COOC(CH_3)_3$, $-CH_2-$piperidinyl(CH_3), $-CH_2-CH_2-$morpholine, $-CH_2-CH_2-OCH_3$, $-CH_2-CH_2-N(CH_3)_2$, azetidinyl, $-CH_2-CH_2-OH$, $-CH_2-CH_2-$piperizinyl$(COCH_3)$ or $-CH_2-COOH$;

$R_{3,}$ at each occurrence, independently, represents hydrogen, alkyl, haloalkyl, acyl, oxo, -OH, heteroaryl, heterocycloalkyl or cycloalkyl, wherein the alkyl, at each occurrence, is optionally substituted with 1 to 3 occurrence(s) of R_{3A}; the heteroaryl is optionally substituted with 1 to 3 occurrence(s) of R_{3B}; and heterocycloalkyl is optionally substituted with 1 to 3 occurrence(s) of R_{3C};

$R_{3A,}$ at each occurrence, independently, is alkoxy, –OH, -CONHOH or -NHCO-alkyl;

$R_{3B,}$ at each occurrence, independently, is alkyl, alkoxy, –OH, -COOH, oxo, -COO-alkyl, -CONH-alkyl or -CONH-OH;


$R_{3C,}$ at each occurrence, independently, is alkyl, -CN, –OH, $-NH_2$, $-N(alkyl)_2$, acyl, oxo, -CONH-alkyl, -NHCO-alkyl or –CONH-alkyl-OH;

$R_{4,}$ at each occurrence, independently, represents hydrogen, $-CH_3$, $-CH_2CH_3$, $-CH_2COOH$, $-CH_2$(*p*-(OCH_3)phenyl), $-CHF_2$, $-COCH_3$, $-CH_2CONHCH_3$ or $-CONHCH_3$;

m is 1, 2 or 3; and

n is 1 or 2.

33. The compound of claim 1, represented by compound of formula (IF):



(IF)

or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof.

34. The compound of claim 33, wherein

X_2 represents CH or N;

R_a represents hydrogen, $-CH_3$, $-CH(CH_3)_2$, $-CH_2-COOC(CH_3)_3$, $-CH_2$-piperidinyl(CH_3), $-CH_2-CH_2$-morpholine, $-CH_2-CH_2-OCH_3$, $-CH_2-CH_2-N(CH_3)_2$, azetidinyl, $-CH_2-CH_2-OH$, $-CH_2-CH_2$-piperizinyl($COCH_3$) or $-CH_2-COOH$;

$R_{3,}$ at each occurrence, independently, represents alkoxy, haloalkyl, -OH, heteroaryl or heterocycloalkyl, wherein the heteroaryl is optionally substituted with 1 to 3 occurrence(s) of R_{3B}; and heterocycloalkyl is optionally substituted with 1 to 3 occurrence(s) of R_{3C};

$R_{3B,}$ at each occurrence, independently, is alkyl, alkoxy, –OH, -COOH, oxo, -COO-alkyl, -CONH-alkyl or -CONH-OH;


$R_{3C,}$ at each occurrence, independently, is $-CH_3$, acyl, -CONH-alkyl or -NHCO-alkyl;

$R_{4,}$ at each occurrence, independently, represents hydrogen, $-CH_3$, $-CH_2CH_3$ or $-CH_2COOH$;

m is 1, 2 or 3; and

n is 1 or 2.

35. The compound of claim 1, represented by compound of formula (IG):



(IG)

or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof.

36. The compound of claim 35, wherein

R_a represents $-CH_3$, $-CH(CH_3)_2$, $-CH_2-COOC(CH_3)_3$, -CH2-piperidinyl(CH_3), $-CH_2-CH_2$-morpholine, $-CH_2-CH_2-OCH_3$, $-CH_2-CH_2-N(CH_3)_2$, azetidinyl, $-CH_2$-oxazole, $-CH_2-CH_2-OH$, $-CH_2-CH_2$-piperizinyl($COCH_3$), $-CH_2-COOH$, $-CH_2-CONH(OCH_3)$, $-CHF_2$ or $-CH_2-CHF_2$;

$R_{3,}$ at each occurrence, independently, represents –CH_3, –CH_2OH, $-CH_2CONHOH$, -F, –CN, $-OCH_3$, $-CHF_2$, $-CF_3$, -CHO, acyl, $-CONHCH_3$, $-COOCH_3$, -




COOH, oxo, -OH, -SO_2NH_2, -SO_2NHCH_3, -$SO_2N(CH_3)_2$, -SO_2NH(phenyl), -$SOCH_3$, -SO_2CH_3, -$SO_2CH(CH_3)_2$, -$SO_2NHCOCH_3$, -$SO_2NHCOCF3$, -$S(O)(NH)CH_3$, -$NHSO_2CH_3$, -$NHSO_2CH_2CH_3$, -$NHSO_2CH(CH_3)_3$, -$NHCOCH_3$, -$N(CH_3)COCH_3$, pyrazolyl, pyridyl, tetrazolyl or thienyl; wherein the pyrazolyl, pyridyl, tetrazolyl and thienyl are optionally substituted with 1 to 3 substituent(s) independently selected from alkyl, alkoxy, –OH, -COOH, oxo, -COO-alkyl, -CONH-alkyl and -CONH-OH;







R_4, at each occurrence, independently, represents hydrogen, -CH_3, -CH_2CH_3, -CH_2COOH, -CH_2(*p*-(OCH_3)phenyl), -CHF_2, -$COCH_3$, -$CH_2COOCH_2CH_3$, -$CH_2CONHCH_3$, -$CONHCH_3$, oxo, -$SO_2CH_2CH_3$, morpholinyl, pyranyl or cyclopropyl; wherein the morpholinyl, pyranyl and cyclopropyl are optionally substituted with 1 to 3 substituent(s) independently selected from -OCH_3, -$COOCH_2CH_3$, -COOH and –$CONHCH_3$;







m is 1, 2 or 3; and







n is 1 or 2.







37. The compound of any one of claims 1 to 36, is selected from:







Example	Structure
1	 ;
2	 ;
3	 ;







4	 ;
5	 ;
6	 ;
7	 ;
8	 ;
9	 ;







10	 ;
11	 ;
12	 ;
13	 ;
14	 ;
15	 ;








16	 ;
17	 ;
18	 ;
19	 ;
20	 ;
21	 ;







22	 ;
23	 ;
24	 ;
25	 ;
26	 ;
27	 ;







28	 ;
29	 ;
30	 ;
31	 ;
32	 ;
33	 ;







34	 ;
35	 ;
36	 ;
37	 ;
38	 ;
39	 ;







40	 ;
41	 ;
42	 ;
43	 ;
44	 ;
45	 ;







46	 ;
47	 ;
48	 ;
49	 ;
50	 ;
51	 ;
52	 ;








53	 ;
54	 ;
55	 ;
56	 ;
57	 ;
58	 ;







59	 ;
60	 ;
61	 ;
62	 ;
63	 ;
64	 ;








65	 ;
66	 ;
67	 ;
68	 ;
69	 ;
70	 ;








71	 ;
72	 ;
73	 ;
74	 ;
75	 ;
76	 ;








77	 ;
78	 ;
79	 ;
80	 ;
81	 ;
82	 ;







83	 ;
84	 ;
85	 ;
86	 ;
87	 ;
88	 ;
89	 ;








90	 ;
91	 ;
92	 ;
93	 ;
94	 ;
95	 ;







96	 ;
97	 ;
98	 ;
99	 ;
100	 ;
101	 ;
102	 ;







103	 ;
104	 ;
105	 ;
106	 ;
107	 ;
108	 ;
109	 ;







110	 ;
111	 ;
112	 ;
113	 ;
114	 ;
115	 ;
116	 ;







117	 ;
118	 ;
119	 ;
120	 ;
121	 ;
122	 ;







123	 ;
124	 ;
125	 ;
126	 ;
127	 ;
128	 ;
129	 ;






130	 ;
131	 ;
132	 ;
133	 ;
134	 ;
135	 ;







136	 ;
137	 ;
138	 ;
139	 ;
140	 ;
141	 ;







142	 ;
143	 ;
144	 ;
145	 ;
146	 ;
147	 ;







148	 ;
149	 ;
150	 ;
151	 ;
152	 ;
153	 ;







154	 ;
155	 ;
156	 ;
157	 ;
158	 ;
159	 ;







160	 ;
161	 ;
162	 ;
163	 ;
164	 ;







165	 ;
166	 ;
167	 ;
168	 ;
169	 ;
170	 ;







171	 ;
172	 ;
173	 ;
174	 ;
175	 ;
176	 ;







177	 ;
178	 ;
179	 ;
180	 ;
181	 ;
182	 ;







183	 ;
184	 ;
185	 ;
186	 ;
187	 ;
188	 ;







189	 ;
190	 ;
191	 ;
192	 ;
193	 ;
194	 ;








195	 ;
196	 ;
197	 ;
198	 ;
199	 ;
200	 ;







201	 ;
202	 ;
203	 ;
204	 ;
205	 ;
206	 ;







207	 ;
208	 ;
209	 ;
210	 ;
211	 ;
212	 ;




213	 ;
214	 ;
215	 ;
216	 ;
217	 ;
218	 ;

219	 ;
220	 ;
221	 ;
222	 ;
223	 ;
224	 ;

225	 ;
226	 ;
227	 ;
228	 ;
229	 ;
230	 ;
231	 ;

232	 ;
233	 ;
234	 ;
235	 ;
236	 ;
237	 ;

238	 ;
239	 ;
240	 ;
241	 ;
242	 ;
243	 ;

244	 ;
245	 ;
246	 ;
247	Isomer-1 of Example 35;
248	Isomer-2 of Example 35;
249	Isomer-1 of Example 99;
250	Isomer-2 of Example 99;
251	Isomer-1 of Example 227; and
252	Isomer-2 of Example 227;

or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof.

38. A pharmaceutical composition comprising the compound of any one of claims 1 to 37 or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier or excipient.

~~39. The pharmaceutical composition comprising the compound of any one of claims 1 to 37 for use in the treatment of CBP and/or EP300 mediated disorder.~~

~~40. A compound according to any one of claims 1 to 37 or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof, for use as a medicament.~~

41. A method of treating a CBP and/or EP300 mediated disease or disorder in a subject comprising administering the subject in need thereof a therapeutically effective amount of compound of formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof, according to any one of claims 1 to 37.

42. The method of claim 41, wherein CBP and/or EP300 mediated disease or disorder is a fibrotic lung disease selected from idiopathic pulmonary fibrosis, fibrotic interstitial lung disease, interstitial pneumonia, fibrotic variant of non-specific interstitial pneumonia, cystic fibrosis, lung fibrosis, chronic obstructive pulmonary lung disease (COPD) and pulmonary arterial hypertension.

43. The method of claim 41, wherein the CBP and/or EP300 mediated disease or disorder is a cancer selected from acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cancer of male and female reproductive system, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, gastro-intestinal tumors including GIST, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, head and neck squamous cell carcinoma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer,

osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor.

44. The method of claim 41, wherein the CBP and/or EP300 mediated disease or disorder is an inflammatory diseases, an inflammatory conditions, and an autoimmune diseases, selected from Addison's disease, acute gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's disease, bullous skin diseases, chronic obstructive pulmonary disease (COPD), Crohn's disease, dermatitis, eczema, giant cell arteritis, glomerulonephritis, hepatitis,hypophysitis, inflammatory bowel disease, Kawasaki disease, lupus nephritis, multiple sclerosis, myocarditis, myositis, nephritis, organ transplant rejection, osteoarthritis, pancreatitis, pericarditis, Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis, sclerosing cholangitis, sepsis, systemic lupus erythematosus, Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis and Wegener's granulomatosis.

45. Compound of any one of claims 1 to 37, or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof, for use in the treatment of CBP and/or EP300 mediated disease or disorder.

46. The compound for use of claim 45, wherein CBP and/or EP300 mediated disease or disorder is

a) a fibrotic lung disease selected from idiopathic pulmonary fibrosis, fibrotic interstitial lung disease, interstitial pneumonia, fibrotic variant of non-specific interstitial pneumonia, cystic fibrosis, lung fibrosis, chronic obstructive pulmonary lung disease (COPD) and pulmonary arterial hypertension; or

b) a cancer selected from acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer,

~~breast cancer, bronchogenic carcinoma, cancer of male and female reproductive system, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, gastro-intestinal tumors including GIST, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, head and neck squamous cell carcinoma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor.~~

~~c) an inflammatory diseases, an inflammatory conditions, and an autoimmune diseases, selected from Addison's disease, acute gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's disease, bullous skin diseases, chronic obstructive pulmonary disease (COPD), Crohn's disease, dermatitis, eczema, giant cell arteritis, glomerulonephritis, hepatitis,hypophysitis, inflammatory bowel disease, Kawasaki disease, lupus nephritis, multiple sclerosis, myocarditis, myositis, nephritis, organ~~

~~transplant rejection, osteoarthritis, pancreatitis, pericarditis, Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis, sclerosing cholangitis, sepsis, systemic lupus erythematosus, Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis and Wegener's granulomatosis.~~

~~47.~~39. Use of a compound of any one of claims 1 to 37, or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an N-oxide or an ester thereof, in the manufacture of a medicament for the treatment of CBP and/or EP300-mediated disease or disorder.

~~48.~~40. The use of claim ~~47~~39, wherein the CBP and/or EP300-mediated disease or disorder is

a) a fibrotic lung disease selected from idiopathic pulmonary fibrosis, fibrotic interstitial lung disease, interstitial pneumonia, fibrotic variant of non-specific interstitial pneumonia, cystic fibrosis, lung fibrosis, chronic obstructive pulmonary lung disease (COPD) and pulmonary arterial hypertension; or

b) a cancer selected from acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cancer of male and female reproductive system, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, gastro-intestinal tumors including GIST, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, head and neck squamous cell carcinoma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative

disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor.

c) an inflammatory diseases, an inflammatory conditions, and an autoimmune diseases, selected from Addison's disease, acute gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's disease, bullous skin diseases, chronic obstructive pulmonary disease (COPD), Crohn's disease, dermatitis, eczema, giant cell arteritis, glomerulonephritis, hepatitis, hypophysitis, inflammatory bowel disease, Kawasaki disease, lupus nephritis, multiple sclerosis, myocarditis, myositis, nephritis, organ transplant rejection, osteoarthritis, pancreatitis, pericarditis, Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis, sclerosing cholangitis, sepsis, systemic lupus erythematosus, Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis and Wegener's granulomatosis.